Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IL-12 gene Clear all
Not yet recruiting Not applicable Interventional

Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD

NCT07121920
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease), IBD, IBD - Inflammatory Bowel Disease
Interventions
Confocal Laser Endomicroscopy
Device
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
2 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Arlington, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 28, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT04367675
View directory record Official record
Conditions
BRCA1/2 Mutation
Interventions
INO-5401, INO-9012, Cellectra 2000
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

NCT00005655
View directory record Official record
Conditions
Kidney Neoplasm, Lung Neoplasm, Sarcoma, Breast Neoplasm
Interventions
rh IL-12, rh IL-2
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

NCT03281382
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ad5-yCD/mutTKSR39rep-hIL12
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Women With Metastatic Breast Cancer

NCT00849459
View directory record Official record
Conditions
Breast Cancer
Interventions
adenovirus-mediated human interleukin-12
Biological
Lead sponsor
Max Sung
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 28, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

NCT02062827
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
Interventions
M032 (NSC 733972)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer

NCT01440816
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12 Electroporation Malignant Melanoma

NCT01502293
View directory record Official record
Conditions
Melanoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 28, 2026, 2:39 AM EDT
Not listed Phase 2 Interventional

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

NCT03132675
View directory record Official record
Conditions
Stage III/IV Melanoma
Interventions
tavokinogene telseplasmid, Pembrolizumab, ImmunoPulse
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
23
States / cities
Tucson, Arizona • Yuma, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 28, 2026, 2:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

NCT07346144
View directory record Official record
Conditions
Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
TGX-007, Valaciclovir
Drug
Lead sponsor
Trogenix ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

NCT00115960
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA, IL-15 DNA adjuvant, IL-12 DNA adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 2:39 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

NCT01236573
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Fludarabine, Cyclophosphamide, IL-12 transduced TIL
Drug · Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 66 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 28, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

NCT01457131
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
Interventions
Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Vector Delivery of the IL-12 Gene in Men With Prostate Cancer

NCT00406939
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
IL-12 gene
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2008 · Synced Oct 28, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12/MK-3475 in Metastatic Melanoma

NCT02493361
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, pIL-12
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 28, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

NCT04627675
View directory record Official record
Conditions
SARS-CoV-2
Interventions
CORVax, IL-12 plasmid, Cliniporator
Drug · Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

NCT00528489
View directory record Official record
Conditions
HIV Infections
Interventions
PennVax B, IL-12, IL-15
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 2:39 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

NCT03491683
View directory record Official record
Conditions
Glioblastoma
Interventions
INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide
Biological · Radiation · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional

Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases

NCT00028652
View directory record Official record
Conditions
Metastatic Cancer
Interventions
interleukin-12 gene
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

NCT02555397
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-yCD/mutTKSR39rep-hIL12
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Not applicable Interventional

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

NCT00323206
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IL-12p DNA, Intratumoral Electroporation
Biological · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

NCT00026143
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 28, 2026, 2:39 AM EDT